A study to evaluate the efficacy, safety, and tolerability of Olpasiran (AMG890, a small interfering RNA) in subjects with elevated lipoprotein(a). MAIN RESULTS: Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease N Engl J Med  2022 Nov 17;387(20):1855-1864. PRESENTATIONS Reduction of Lipoprotein(a) With Small Interfering RNA – Results of the OCEAN(a)-DOSE (TIMI 67) Trial … Continue reading OCEAN(a)-DOSE -TIMI 67